Jornal da Leucemia
Acesso livre

Abstrato

12-O-Tetradecanoylphorbol-13-Acetate for Refractory Secondary Acute Myeloid Leukemia

Quande Lin, Baijun Fang, Yufu Li, Jianwei Du and Yongping Song

In December 2011, a 42-year-old woman was referred to our department. The patient was previously diagnosed with breast cancer in June 2009. She received 6 courses of chemotherapy after having breast tumor resection, and achieved complete remission (CR) after chemotherapy. Then tamoxifen was given for 6 months as a subsequent endocrine therapy. In September 2011, the patient was diagnosed with acute myeloid leukemia-M2 (AML-M2) due to a fever of 39.0. The routine blood test indicated that the white blood count(WBC) was 43.67×109/L, absolute neutrophil count (ANC) was 0.8×109/L, hemoglobin was 57 g/L, platelets count was 22×109/L, and the myeloblasts accounted for 48% in the peripheral blood as well as 79% in the bone marrow.